



**INTERNATIONAL JOURNAL OF
PHARMACEUTICAL SCIENCES**
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: <https://www.ijpsjournal.com>



Review Paper

Quality By Design (QbD) Implementation Challenges in Indian Pharmaceutics

Sakshi Giri*, Bhagwan Gite, Jyoti Shingate, Dr. Swati Burungale, Dr. Rajendra Patil

Delonix Society's Baramati College of Pharmacy, Barhanpur, Maharashtra, India.

ARTICLE INFO

Published: 14 July 2026

Keywords:

QbD, PAT, ICH, DoE,
QTPP, CQA, CMA, CPP,
Design Space, Control
Strategy

DOI:

10.5281/zenodo.21352351

ABSTRACT

Quality by Design (QbD) represents a paradigm shift from empirical, end-product testing toward a science- and risk-based framework that systematically embeds quality into product and process development. Initially institutionalized within pharmaceutical regulatory frameworks through ICH Q8 (R2), Q9, and Q10 guidelines, QbD has evolved into a comprehensive lifecycle management strategy encompassing product development, process optimization, control strategy establishment, and continuous improvement. This review critically evaluates the conceptual evolution, regulatory foundations, mechanistic components, and industrial applications of QbD. Particular emphasis is placed on its expanding role in herbal drug development and medicinal plant standardization, where intrinsic biological variability poses significant quality challenges. The integration of multivariate statistical tools, design of experiments (DoE), process analytical technology (PAT), and chemometric profiling has enabled the translation of QbD principles into phytopharmaceutical research. Despite demonstrable advantages—including enhanced regulatory flexibility, reduced batch failures, and improved process robustness—barriers such as data complexity, high implementation cost, and lack of global harmonization remain. Emerging digital technologies including artificial intelligence, digital twins, and blockchain systems are poised to augment QbD-based predictive control models. This manuscript provides a critical synthesis of current evidence and identifies future research directions necessary for strengthening QbD implementation across synthetic and plant-based medicinal products.

INTRODUCTION

QbD is described as "a systematic approach to development that begins with predefined

objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management" in ICH Q8 (R2).

***Corresponding Author:** Sakshi Giri

Address: Delonix Society's Baramati College of Pharmacy, Barhanpur, Maharashtra, India..

Email ✉: girisakshi41@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



Three fundamental pillars are highlighted in this definition: risk-based control, mechanistic process understanding, and predetermined quality objectives. The QbD framework was first developed for synthetic pharmaceutical products, but it has shown growing applicability in biologics, nanomedicine, advanced drug delivery systems, and, more recently, phytopharmaceuticals and formulations derived from medicinal plants. Pharmaceutical companies are realizing more and more how important product efficacy, safety, and quality are. Product quality has significantly improved as a result of the application of QbD scientific methods. While QbD-based tools reduce risks by improving both quality and operational productivity, these techniques provide clear, crucial insights from initial product design to final production.(1,2,3)

1.1. QbD, or quality by design: Instead of relying only on end-product testing, the Quality by Design (QbD) methodology is a systematic approach to pharmaceutical development that prioritizes designing quality into products at the outset. Understanding the relationship between raw materials, production processes, and the final product is fundamental to ensuring consistent quality. QbD includes defining quality attributes, identifying critical parameters, and employing risk management to lower variability.(4,5,6)

Quality by Design Elements:

1. Quality Target Product Profile (QTPP):

QTPP outlines predetermined goals that a pharmaceutical product must meet over the course of its life. The intended therapeutic performance, safety profile, administration route, dosage form, and stability parameters are all outlined in this strategic blueprint.

2. Critical Quality Attributes (CQAs):

CQAs are measurable biological, microbiological, or physicochemical traits that have a direct bearing

on efficacy and safety. Risk assessment, statistical correlation with clinical outcomes, and mechanistic understanding are necessary for their identification.

3. Critical Process Parameters (CPPs) and Critical Material Attributes (CMAs):

CPPs are operational variables whose fluctuations may affect product quality, while CMAs are intrinsic qualities of raw materials that affect CQAs. To clarify parameter interactions, multivariate Design of Experiments (DoE) approaches are frequently used.

4. Design Space and Control Strategy:

The design space is a multifaceted area where product quality is not jeopardized by process variability. Regulatory bodies encourage scientific rigor during development by allowing operational flexibility in this area without requiring prior approval.

5. Continuous Improvements:

This is a Quality by Design tenet. In order to guarantee consistent product quality, improve process efficiency, and comply with regulations, pharmaceutical manufacturing processes are continuously carried out throughout the product life cycle.(7,8,9)

3. Risk Assessment Tools QbD:

Tools for risk assessment are used to find, evaluate, and rank variables that could have an impact on the quality of a product. Typical tools are as follows:

Ishikawa (Fishbone) Diagram: A tool for cause-and-effect analysis that can be used to find possible sources of variability that could impact the quality of a product.

A methodical approach to analyzing possible failure modes and their effects on product performance is called Failure Mode and Effects Analysis (FMEA).



A qualitative or semi-quantitative method for ranking risks based on likelihood and severity is called risk ranking and filtering (RRF).

A preventive risk-management tool called Hazard Analysis and Critical Control Points (HACCP) is used to pinpoint and manage critical manufacturing process points.(10,11)

4.Implementation Challenges of QbD in the Indian Pharmaceutical Industry:

The adoption of Quality by Design (QbD) has become increasingly important in the Indian pharmaceutical industry because of the need for strong product quality and rising regulatory expectations. However, a number of obstacles prevent it from being widely used. The following is a review article discussion of the main implementation challenges:

1. Insufficient Technical Knowledge:

The lack of personnel with the necessary training is one of the main obstacles to QbD implementation in India. Professionals with adequate understanding of QbD principles, risk assessment methods, statistical tools, and Design of Experiments (DoE) are scarce in many pharmaceutical companies. This restricts the efficient use of risk-based and scientific methods in product development.

2. Large Initial Outlay:

Adopting QbD necessitates a significant financial outlay for software tools, process analytical technology (PAT), advanced analytical instruments, and staff training initiatives. These expenditures could be very costly, especially for small and medium-sized pharmaceutical businesses.

3. Insufficient Knowledge of Regulations:

Despite the encouragement of QbD-based development by regulatory bodies like the USFDA, EMA, and ICH, many Indian pharmaceutical manufacturers are not well-versed in regulatory requirements and expectations. The

successful application of QbD practices is frequently delayed by a lack of knowledge about guidelines like ICH Q8, Q9, and Q10.

4. Experimental Design Complexity:

To determine the relationships between crucial material attributes, process parameters, and product quality attributes, QbD makes extensive use of statistical methodologies and Design of Experiments (DoE). For businesses without statistical analysis experience, the intricacy of experimental design and data interpretation can be difficult.

5. Insufficient Technology and Infrastructure:

Many pharmaceutical businesses, particularly small-scale producers, use traditional production facilities and have restricted access to cutting-edge technologies. The application of contemporary QbD concepts is limited by the lack of advanced analytical tools and automation systems.

6. Resistance to Organizational Change:

The transition from traditional quality-by-testing approaches to a science-based QbD framework requires significant changes in organizational culture and operational practices. Resistance from management and employees toward adopting new methodologies often hampers successful implementation.

7. Extensive Documentation Requirements:

QbD generates a large volume of scientific data and documentation throughout the product lifecycle. Maintaining comprehensive records, preparing regulatory submissions, and ensuring data integrity require considerable time and resources, which may increase the operational burden on pharmaceutical companies.

8. Data Management and Knowledge Integration:

Effective implementation of QbD depends on the collection, analysis, and integration of large amounts of process and product data. Inadequate data management systems and poor knowledge-sharing practices can limit the development of a



comprehensive understanding of manufacturing processes.

9. Extended Time for Development:

Product development timelines may be extended due to the systematic approach of QbD, which necessitates extensive experimentation and process optimization. As a result, some manufacturers believe that implementing QbD requires a lot of time and resources.

10. Limited Uptake by Small and Medium-Sized Businesses:

Due to budgetary limitations, a lack of experience, and inadequate technological capabilities, QbD adoption among small and medium-sized pharmaceutical companies in India is still restricted despite its long-term advantages.(12,13,14)

5. Difficulties and quality by design in the future:

Despite the fact that Quality by Design is a crucial component of the contemporary approach to pharmaceutical quality, implementation is hampered by a lack of knowledge about the pharmaceutical process.

Most pharmaceutical companies believe that more straightforward instructions on how to actually apply QbD are needed. Businesses requested clarification from the FDA regarding QbD terminology, approved procedures, standards for determining control sufficiency, criteria for substituting analytical methods, and criteria for choosing and rejecting critical quality attributes. The main obstacles to the adoption of QbD are ten. These difficulties are assessed based on how relevant they are to various drug types and adoption levels.

The first four issues arise in businesses: 1. Internal misalignment (disconnect between cross-functional areas, such as manufacturing and R&D or quality and regulatory) 2. Lack of faith in the business case, meaning that the investment and timing of QbD implementation are highly

uncertain. 3. Insufficient technology to carry out (e.g., challenging data management, inadequate comprehension of the application of CQA. 4. Alignment with third parties (e.g., How can QbD be implemented while relying more on contract manufacturers and suppliers?) (The following six issues have a direct bearing on the regulatory body:

1. Variations in how QbD is handled by different regulatory bodies.
2. Absence of concrete guidance for business.
3. Regulators are ill-equipped to manage QbD applications .
4. There is a lack of confidence in the way promised regulatory benefits are currently being distributed.
5. International regulatory bodies' misalignment.
6. QbD Future Perspective is not supported by current interactions with businesses.

"Quality by Design" implies "the right analysis at the right time" and is founded on risk assessment and science, but it does not necessarily imply "less analytical testing." Pharmaceutical companies are putting quality by design (QbD) into practice because it helps to establish robust and rough methods that help to comply with ICH guidelines. It implies that processes like risk assessment, design space, CQA, and target profile are equally applicable to analytical techniques. Quality by design will become much more common in the future. Because it is currently frequently used in the development space, where we tend to use the event approach within the method, it will also be applied in the production space.(15,16,17)

6. Methods for Overcoming These Obstacles

1. Make training program investments with a QbD focus.
2. Adopt a phased implementation strategy as opposed to an organization-wide deployment.
3. Make good use of DoE tools and statistical software.



4. Increase industry-academia cooperation.
5. Enhance digitalization and data integrity systems.
6. Create internal subject-matter experts in QbD.
7. Gradually incorporate risk-management and PAT techniques.(18,19)

7. QbD BENEFITS:

1. Better product quality: Rather than depending solely on final testing, quality is integrated into the product from the development stage.
2. Improved process comprehension: Important elements influencing product quality are recognized and managed.
3. Less manufacturing variability results in more reliable product performance.
4. Reduced failure risk: Possible issues are found and fixed early.
5. Cost savings: fewer product recalls, reworks, and batch failures.
6. Regulatory flexibility: Because QbD-based methods show a scientific grasp of the process, regulatory bodies frequently support them.
7. Effective scale-up: A simpler transition from lab to industrial production.(20,21,22)

CONCLUSIONS

Throughout the development process, the quality of pharmaceutical goods may be guaranteed according to a revolutionary framework called Quality by Design (QbD). Manufacturers may dramatically lower variability, improve efficiency, and more closely conform to regulatory standards by integrating quality issues from the beginning. The longterm benefits—such as less product failures and improved patient safety—far surpass the early expenditures associated with training, resources, and data infrastructure. The production of safe and effective pharmaceuticals will depend increasingly on QbD as the pharmaceutical industry develops, especially with advances in automation, artificial intelligence, and continuous

manufacturing. The necessity for flexible QbD solutions that can accommodate a range of patient demographics is underscored by emerging concepts, such as customized medicine. Prospects for QbD in the future include integrating digital technologies even more to improve data analysis and expedite procedures.

REFERENCES

1. Beg S, Hasnain MS, Rahman M, Swain S. Introduction to quality by design (QbD): fundamentals, principles, and applications. In: *Pharmaceutical Quality by Design*. New Delhi: Academic Press; 2019. 1–17p.
2. Nadpara NP, Thumar RV, Kalola VN, Patel PB. Quality by design (QBD): A complete review. *Int J Pharm Sci Rev Res*. 2012; 17(2): 20–28p.
3. Calhan SD, Eker ED, Sahin NO. Quality by design (QbD) and process analytical technology (PAT) applications in pharmaceutical industry. *European Journal of Chemistry*. 2017; 8(4): 430–433p.
4. U.S. Food and Drug Administration (FDA). (2006). *Pharmaceutical quality for the 21st century: A risk-based approach*. U.S. Department of Health and Human Services. <https://www.fda.gov/media/77391/download>
5. International Conference on Harmonisation (ICH). (2009). Q8(R2) pharmaceutical development. https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf
6. International Conference on Harmonisation (ICH). (2012). Q9: Quality risk management. https://database.ich.org/sites/default/files/Q9_Guideline.pdf
7. International Conference on Harmonisation (ICH). (2008). Q10: Pharmaceutical quality system. https://database.ich.org/sites/default/files/Q10_Guideline.pdf



8. Patil, A. S., & Pethe, A. M. (2013). Quality by design (QbD): A new concept for development of quality pharmaceuticals. *International Journal of Pharmaceutical Quality Assurance*, 4(2), 1319. <https://www.researchgate.net/publication/n/269107872> Quality by Design_QbD_A_New_Concept_for_Development_of_Quality_Pharmaceuticals.
9. Montgomery, D. C. (2017). *Design and analysis of experiments* (9th ed.). Wiley. <https://www.wiley.com/enus/Design+and+Analysis+of+Experiments%2C+9th+Edition-p-9781119113478> 7.
10. Yu, L. X., Amidon, G., Khan, M. A., & Hoag, S. W. (2014). Understanding pharmaceutical quality by design. *European Journal of Pharmaceutics and Biopharmaceutics*, 91, 1-13. <https://www.sciencedirect.com/science/article/pii/S0939641114001861>
11. U.S. Food and Drug Administration (FDA). (2011). *Process validation: General principles and practices*. U.S. Department of Health and Human Services. <https://www.fda.gov/media/71021/download>
12. Kourti, T. (2010). Process analytical technology and quality by design. *Analytical and Bioanalytical Chemistry*, 398(1), 53-58. <https://link.springer.com/article/10.1007/s00216-010-3699-1>
13. Lionberger, R. A., Lee, S. L., Lee, L., & Raw, A. (2008). Quality by design: Concepts for ANDAs. *The AAPS Journal*, 10(2), 268-276. <https://pubmed.ncbi.nlm.nih.gov/18800218/>
14. Basu, P. K., & Walker, S. (2012). Implementing Quality by Design (QbD) in generic pharmaceutical product development. *Journal of Pharmaceutical Innovation*, 7(1), 22-31. <https://doi.org/10.1007/s12247-012-9125-1>
15. Rathore, A. S., & Winkle, H. (2009). Quality by Design for biopharmaceuticals. *Nature Biotechnology*, 27(1), 26-34. <https://doi.org/10.1038/nbt0109-26>
16. Anusha T, Shyamala, Sharma JVC. Quality by design and its applications. *World Journal of Pharmaceutical and Life Sciences*. 2020;6(1):180-186.
17. Nadpara NP, Thumar RV, Kalola VN, Patel PB. Quality by Design: A complete review. *International Journal of Pharmaceutical Sciences Review*.
18. Priya B. Shah Khushbu Patel. Qbd – A novel setup for the analytical method development. *World Journal of Pharmacy and Pharmaceutical Sciences*. 2021;10(5):1645-1662.
19. Divyesh Sharma, Khushbu Patel and Dr. C. N. Patel. QbD-A new era of Pharmaceutical drug development *European Journal of Pharmaceutical and Medical Research*. 2021; 8(5):688-694.
20. Gaydhane NK, More MP, Thomble VV, Polkare GM, Tale RR, Bakal RL, et al. A Review of Implementing Quality by Design. *Annals of Pharma Research*. 2022;10(9):718-730.
21. angshetti JN, Deshpande M, Zaheer Z, Shinde DB, Arote R. Quality by Design approach: Regulatory Need. *Arabian Journal of Chemistry*, 2017, 10.
22. Rajput JM, Nandre DS, Jayswal BJ. Quality by Design Approach: Regulatory Guidelines and Current Status. *International Journal for Research Trends and Innovation*, 2022, 7(6).

HOW TO CITE: Sakshi Giri, Bhagwan Gite, Jyoti Shingate, Dr. Swati Burungale, Dr. Rajendra Patil, Quality By Design (QBD) Implementation Challenges in Indian Pharmaceutics, *Int. J. of Pharm. Sci.*, 2026, Vol 4, Issue 7, 2774-2779, <https://doi.org/10.5281/zenodo.21352351>

